nerve pain neuropathic pain
Conditions
Interventions
This trial will be conducted following a complete counterbalancing design.
Each patient will be treated with four different doses of S(+)-ketamine (0, 50,
75, and 100 mg) in a random treatment seque
Sponsors
Medisch Centrum Alkmaar
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: patients with neuropathic pain (more than 6 months present) as defined by the IASP Pain detect score > 18 and pain intensity VAS score > 6and the presence of Allodynia (VAS score >4) age between 18 and 75 written informed consent
Exclusion criteria
Exclusion criteria: pregnancy known hypersensitivity towards S(+)-ketamine patients with psychiatric history or under treatment patients with Angina pectoris, acute myocardial infarction, heart failure, heart rhythm disorder patients with a pacemaker and/or an implantable cardioverter defibrillator patients with uncontrollable arterial hypertension patients with glaucoma patients with uncontrollable thryroid dysfunction Hospital Anxiety and Depression Scale (HADS-NL) score > 8 for depression and/or > 8 for anxiety No new analgesic treatment may be initiated 6 weeks before start of the study No change in analgesic treatment may be performed during the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - overall pain relief. Measurement of pain intensity using a VAS-score | — |
Secondary
| Measure | Time frame |
|---|---|
| impact of S(+)-ketamine treatment on quality of life impact of S(+)-ketamine treatment on health status(Pain disability index) impact of S(+)-ketamine treatment on symptoms of neuropathic pain | — |
Countries
Netherlands
Outcome results
None listed